Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

NCT03019757 · View on ClinicalTrials.gov ↗

Study Summary

The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.

Interventions

  • RADIATION DaTscan
  • RADIATION F18-AV-45
  • RADIATION FDG-PET
  • GENETIC APOE genotype
  • PROCEDURE Polysomnogram

Study Locations (1)

Ohio

  • The Ohio State University — Columbus

Trial Details

FieldValue
Enrollment Target 76 participants
Start Date 2018-08-30
Est. Completion 2026-12

Sponsor

Douglas Scharre

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03019757

The ClinicalTrials.gov registry entry for NCT03019757 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Douglas Scharre, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 5 interventions — of which DaTscan is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03019757 reports 1 study location spanning 1 distinct geographic area — top geographies include Ohio. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03019757 about?

NCT03019757 is a clinical study titled "Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease". The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.

What is the current status of trial NCT03019757?

This trial is currently recruiting. The enrollment target is 76 participants. The study started on 2018-08-30. Estimated completion is 2026-12.

What conditions does trial NCT03019757 study?

This clinical trial studies the following conditions: Parkinson's Disease, Alzheimer's Disease, Lewy Body Dementia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03019757?

The interventions under investigation include: DaTscan (RADIATION), F18-AV-45 (RADIATION), FDG-PET (RADIATION), APOE genotype (GENETIC), Polysomnogram (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03019757?

This trial is sponsored by Douglas Scharre, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03019757 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial